You are currently viewing a new version of our website. To view the old version click .

Design, Synthesis, and Evaluation of New Anticancer Substances and Radiopharmaceuticals

This special issue belongs to the section “Chemical Biology“.

Special Issue Information

Dear Colleagues,

The development of novel anticancer agents and radiopharmaceuticals remains a multidisciplinary field at the intersection of medicinal chemistry, molecular biology, pharmacology, and nuclear medicine. This research area focuses on the rational design, synthesis, and biological evaluation of new compounds with selective cytotoxicity against cancer cells. A growing emphasis is placed on targeting specific molecular pathways and tumor biomarkers to improve therapeutic efficacy and reduce their systemic toxicity. Radiopharmaceuticals, which combine biologically active molecules with radioactive isotopes, offer both diagnostic and therapeutic (theranostic) potential—enabling personalized treatment strategies and real-time monitoring of therapeutic outcomes. Advances in synthetic methodologies, structure–activity relationship (SAR) studies, and in vitro/in vivo evaluation models are accelerating the translation of promising candidates from bench to bedside. This topic invites contributions highlighting innovative approaches to the design and functional evaluation of small molecules, metal complexes, peptides, or nanoparticles with anticancer and/or radiopharmaceutical applications.

Prof. Dr. Monika Pitucha
Dr. Marta Rusek
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • synthesis
  • anticancer activity
  • radiopharamceuticals
  • organic compounds
  • medicinal chemistry

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Biomolecules - ISSN 2218-273X